Insulin glargine/insulin lispro - Adocia
Alternative Names: BC Combo; BC Combo THDB 0207; BioChaperone Combo; BioChaperone glargine/lispro; Insulin-lispro/insulin-glargineLatest Information Update: 22 Jul 2024
At a glance
- Originator Adocia
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Type 1 diabetes mellitus
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 08 Jul 2024 Tonghua Dongbao Pharmaceutical terminates its license agreement with Adocia for Insulin glargine/insulin lispro (BioChaperone® Combo) in China, Asia and Middle East
- 28 May 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Germany (SC, Injection)
- 28 Feb 2024 Tonghua Dongbao plans a meeting with NMPA for preparing the next stages of development of Insulin glargine/insulin lispro - Adocia